Free Trial
CVE:SLS

Solaris Resources (SLS) Stock Price, News & Analysis

Solaris Resources logo
C$6.15 -0.17 (-2.69%)
As of 02/8/2021

About Solaris Resources Stock (CVE:SLS)

Key Stats

Today's Range
C$5.95
C$6.35
50-Day Range
C$6.15
C$6.15
52-Week Range
C$1.38
C$7.09
Volume
53,313 shs
Average Volume
132,199 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

Remove Ads
Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solaris Resources and its competitors with MarketBeat's FREE daily newsletter.

SLS Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

SLS Stock Analysis - Frequently Asked Questions

Solaris Resources' stock was trading at C$6.15 at the start of the year. Since then, SLS stock has increased by 0.0% and is now trading at C$6.15.
View the best growth stocks for 2025 here
.

Solaris Resources Inc. (CVE:SLS) posted its earnings results on Tuesday, November, 12th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Shares of SLS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Company Calendar

Last Earnings
11/12/2024
Today
3/12/2025

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
CVE:SLS
CIK
N/A
Web
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
N/A
Beta
N/A
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (CVE:SLS) was last updated on 3/12/2025 by MarketBeat.com Staff
From Our Partners